All In Biotech

Drug Trial Radar · NCT06293716

CVL237 Tablets for APDS/PASLI

An Open, Dose-exploration Study, Followed by a Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy and Safety of CVL237 Tablets in Patients With APDS/PASLI

Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

35

Planned (sponsor's estimate)

Start

Mar 30, 2024

Primary completion

Dec 29, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Convalife (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency).

Conditions

  • PI3K and P110delta Hyperactivation Syndrome

Interventions

  • CVL237 tabletsDrug

    CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

  • CVL237 placebo tabletsDrug

    CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. part 1 : Incidence of Treatment-Emergent Adverse EventsTime frame: Throughout the study for approximately 84 days
  2. part 2:After 84 days of treatment, changes in the sum of diameter product (SPD) of log10 conversion in target lesions and changes in the percentage of naive B cells to total B cells from baseline were observedTime frame: At baseline (day 0) and at the end of treatment (day 84)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.